302 related articles for article (PubMed ID: 10986057)
21. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.
García-Donas J; Font A; Pérez-Valderrama B; Virizuela JA; Climent MÁ; Hernando-Polo S; Arranz JÁ; Del Mar Llorente M; Lainez N; Villa-Guzmán JC; Mellado B; González Del Alba A; Castellano D; Gallardo E; Anido U; García Del Muro X; Domènech M; Puente J; Morales-Barrera R; Pérez-Gracia JL; Bellmunt J
Lancet Oncol; 2017 May; 18(5):672-681a. PubMed ID: 28389316
[TBL] [Abstract][Full Text] [Related]
22. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.
Bajorin DF; McCaffrey JA; Dodd PM; Hilton S; Mazumdar M; Kelly WK; Herr H; Scher HI; Icasiano E; Higgins G
Cancer; 2000 Apr; 88(7):1671-8. PubMed ID: 10738226
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group.
Dreicer R; Manola J; Schneider DJ; Schwerkoske JF; George CS; Roth BJ; Wilding G;
Cancer; 2003 Jun; 97(11):2743-7. PubMed ID: 12767086
[TBL] [Abstract][Full Text] [Related]
24. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial.
Pectasides D; Glotsos J; Bountouroglou N; Kouloubinis A; Mitakidis N; Karvounis N; Ziras N; Athanassiou A
Ann Oncol; 2002 Feb; 13(2):243-50. PubMed ID: 11886001
[TBL] [Abstract][Full Text] [Related]
25. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
von der Maase H; Hansen SW; Roberts JT; Dogliotti L; Oliver T; Moore MJ; Bodrogi I; Albers P; Knuth A; Lippert CM; Kerbrat P; Sanchez Rovira P; Wersall P; Cleall SP; Roychowdhury DF; Tomlin I; Visseren-Grul CM; Conte PF
J Clin Oncol; 2000 Sep; 18(17):3068-77. PubMed ID: 11001674
[TBL] [Abstract][Full Text] [Related]
26. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial.
von der Maase H; Andersen L; Crinò L; Weinknecht S; Dogliotti L
Ann Oncol; 1999 Dec; 10(12):1461-5. PubMed ID: 10643537
[TBL] [Abstract][Full Text] [Related]
27. Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study.
Neri B; Vannini L; Giordano C; Grifoni R; Pantaleo P; Baldazzi V; Crisci A; Lapini A; Raugei A; Carini M
Anticancer Drugs; 2007 Nov; 18(10):1207-11. PubMed ID: 17893522
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial.
Lorusso V; Manzione L; De Vita F; Antimi M; Selvaggi FP; De Lena M
J Urol; 2000 Jul; 164(1):53-6. PubMed ID: 10840423
[TBL] [Abstract][Full Text] [Related]
29. Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
Rodriguez J; Cortes J; Calvo E; Azinovic I; Fernandez-Hildago O; Martinez-Monge R; Garzon C; de Irala J; Martinez-Aguillo M; Ramon Y Cajal T; Brugarolas A
Cancer; 2000 Dec; 89(12):2622-9. PubMed ID: 11135224
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
Alva A; Daignault S; Smith DC; Hussain M
Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Hainsworth JD; Meluch AA; Litchy S; Schnell FM; Bearden JD; Yost K; Greco FA
Cancer; 2005 Jun; 103(11):2298-303. PubMed ID: 15856431
[TBL] [Abstract][Full Text] [Related]
32. A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium.
Sweeney CJ; Williams SD; Finch DE; Bihrle R; Foster RS; Collins M; Fox S; Roth BJ
Cancer; 1999 Aug; 86(3):514-8. PubMed ID: 10430261
[TBL] [Abstract][Full Text] [Related]
33. A 3-week gemcitabine-cisplatin regimen for metastatic urothelial cancer.
Winquist E; Wilson JJ; Dorreen M; Wong R; Jonker D; Iscoe N
Can J Urol; 2004 Dec; 11(6):2445-9. PubMed ID: 15636670
[TBL] [Abstract][Full Text] [Related]
34. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network.
Meluch AA; Greco FA; Burris HA; O'Rourke T; Ortega G; Steis RG; Morrissey LH; Johnson V; Hainsworth JD
J Clin Oncol; 2001 Jun; 19(12):3018-24. PubMed ID: 11408496
[TBL] [Abstract][Full Text] [Related]
36. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.
Philips GK; Halabi S; Sanford BL; Bajorin D; Small EJ;
Ann Oncol; 2009 Jun; 20(6):1074-9. PubMed ID: 19168670
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma.
Gitlitz BJ; Baker C; Chapman Y; Allen HJ; Bosserman LD; Patel R; Sanchez JD; Shapiro RM; Figlin RA
Cancer; 2003 Nov; 98(9):1863-9. PubMed ID: 14584068
[TBL] [Abstract][Full Text] [Related]
38. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point.
Small EJ; Lew D; Redman BG; Petrylak DP; Hammond N; Gross HM; Eastham JA; Crawford ED
J Clin Oncol; 2000 Jul; 18(13):2537-44. PubMed ID: 10893284
[TBL] [Abstract][Full Text] [Related]
39. [Combination chemotherapy of paclitaxel, carboplatin and gemcitabine in patients who have received prior cisplatin-based chemotherapy].
Ito H; Aoki Y; Oyama N; Miwa Y; Akino H; Yokoyama O
Gan To Kagaku Ryoho; 2011 Mar; 38(3):481-4. PubMed ID: 21403460
[TBL] [Abstract][Full Text] [Related]
40. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.
Dogliotti L; Cartenì G; Siena S; Bertetto O; Martoni A; Bono A; Amadori D; Onat H; Marini L
Eur Urol; 2007 Jul; 52(1):134-41. PubMed ID: 17207911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
